

Access DB#

68684

## SEARCH REQUEST FORM

## Scientific and Technical Information Center

Requester's full Name: Everett White Examiner #: 67057 Date: 6/13/2002Art Unit: 1623 Phone Number 308-4621 Serial Number: PCT/US02/13037 & 09/843,181Mail Box: CM1-8B19 and Bldg/Room Location: CM1-7B13 Results Format Preferred (circle): PAPER DISK E-MAIL**If more than one search is submitted, please prioritize searches in order of need.**

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, key words, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc; if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See Bib Data SheetInventors (please provide full names): See Bib Data SheetEarliest priority Filing Date: See Bib Data Sheet

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the process for making a dried modified cyclodextrin product of Claims 1-6, the process for making a dried agglomerated modified cyclodextrin product of Claims 7-11, and the dried agglomerated modified cyclodextrin product of Claims 12-18. A copy of the claims and abstract is provided.

The Bib Data Sheet which discloses the inventor names, title of the invention, and the earliest priority filing date is also provided.

Point of Contact:  
Mona Smith  
Technical Information Specialist  
CM1 6A01  
Tel: 308-3278

\*\*\*\*\*

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>M. Smith</u>	NA Sequence (#) <u>STN</u>	
Searcher Phone #: _____	AA Sequence (#) <u>Dialog</u>	
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>6/18/02</u>	Bibliographic <u>X</u>	Dr. Link _____
Date Completed: <u>6/20/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>60</u>	Fulltext _____	Sequence Systems _____
Clerical prep time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>60</u>	Other _____	Other (specify) _____

=> Fil hcaplu  
FILE 'HCAPLUS' ENTERED AT 11:45:59 ON 20 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jun 2002 VOL 136 ISS 25  
FILE LAST UPDATED: 18 Jun 2002 (20020618/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d stat que  
L1 267 SEA FILE=REGISTRY CYCLODEXTRIN?(L)BETA(L)HYDROXYPROPYL?  
L4 2089 SEA FILE=HCAPLUS L1 OR HYDROXYPROPYL?(L)BETA(L)CYCLODEXTRIN?  
L5 703 SEA FILE=HCAPLUS L4 (L)(PREP? OR PROD? OR MANUF? OR PROCESS?)  
L6 102 SEA FILE=HCAPLUS L5 (L)(DRI? OR DRY?)  
L7 4 SEA FILE=HCAPLUS L6 AND PARTIC?(W)SIZE?

=> d ibib abs hitrn 17 1-4

L7 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2001:11362 HCAPLUS  
DOCUMENT NUMBER: 134:212628  
TITLE: Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method  
AUTHOR(S): Skalko-Basnet, Natasa; Pavelic, Zeljka; Becirevic-Lacan, Mira  
CORPORATE SOURCE: Department of Pharmaceutics, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia  
SOURCE: Drug Development and Industrial Pharmacy (2000), 26(12), 1279-1284  
CODEN: DDIPD8; ISSN: 0363-9045  
PUBLISHER: Marcel Dekker, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The one-step spray-drying method was applied in the

**prepn.** of liposomes contg. drug and **cyclodextrin** (CD).  
**Spray-dried** lecithin liposomes, entrapping metronidazole or verapamil alone or together with **hydroxypropyl-.beta.-cyclodextrin** (HP.beta.CD), were characterized for morphol., size distribution, and drug entrapment efficiency. The main factor influencing the liposomal size was the vol. of aq. medium used for hydration of the **spray-dried product**. No differences in size or entrapment between liposomes **prepd.** by immediate hydration of **dried** powder or by hydration after 1 yr of powder storage at 4.degree. were obsd. All liposomes were tested for their serum stability. The most stable liposomes (still retaining about 10% of the originally entrapped drug even after 24 h incubation with serum) were liposomes **prepd.** by the direct **spray-drying** of the mixt. of lipid, drug, and HP.beta.CD.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:84943 HCAPLUS

DOCUMENT NUMBER: 132:270007

TITLE: Chitosan microspheres with hydrocortisone and hydrocortisone-hydroxypropyl-.beta.-cyclodextrin inclusion complex

AUTHOR(S): Filipovic-Grcic, J.; Voinovich, D.; Moneghini, M.; Becirevic-Lacan, M.; Magarotto, L.; Jalsenjak, I.

CORPORATE SOURCE: Faculty of Pharmacy and Biochemistry, Department of Pharmaceutics, University of Zagreb, Zagreb, 10000, Croatia

SOURCE: European Journal of Pharmaceutical Sciences (2000), 9(4), 373-379

CODEN: EPSCED; ISSN: 0928-0987  
 Elsevier Science Ireland Ltd.

PUBLISHER: Journal

DOCUMENT TYPE: English

LANGUAGE: English

AB In the present study, an inclusion complex composed of hydrocortisone acetate (HC) and **hydroxypropyl-.beta.-cyclodextrin** (HP.beta.CD) was **prepd.** by the **spray-drying** method. HC alone, HC inclusion complex or HC with HP.beta.CD as a phys. mixt. were incorporated into chitosan microspheres by **spray-drying**. The inclusion complex and microspheres were characterized by x-ray powder diffractometry and DSC. Microspheres were studied with respect to **particle size** distribution, drug content and in vitro drug release. The HCHP.beta.CD inclusion complex was more water sol. than HC alone. The HC release rates from chitosan microspheres were influenced by the drug/polymer ratio in the manner that an increase in the release rate was obsd. when the drug loading was decreased. However, release data from all samples showed significant improvement of the dissoln. rate for HC, with 25-40% of the drug being released in the first hour compared with about 5% for pure HC. The complexation method and microsphere **prepn.** method (**spray-drying**) is simple with great potential for industrial **prodn.**

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:288023 HCAPLUS  
DOCUMENT NUMBER: 126:334266  
TITLE: Particle and powder properties of cyclodextrins  
AUTHOR(S): Munoz-Ruiz, Angel; Paronen, Petteri  
CORPORATE SOURCE: Department Pharmaceutics, University Kuopio, Kuopio,  
70211, Finland  
SOURCE: Int. J. Pharm. (1997), 148(1), 33-39  
CODEN: IJPHDE; ISSN: 0378-5173  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The particle and powder properties of .alpha.-, .beta.-, .gamma.- and hydroxypropyl-.beta.- (HP.beta.) cyclodextrins (CDs) were examd. Special attention was paid to water interaction and thermal properties of CDs. The CDs studied showed big differences in particle size distribution and particle shape. In all cases, with the exception of .beta.CD, the log-normal distribution described adequately the particle size distribution. However, the .beta.-distribution characterized well particle shape factor distribution. The typical .alpha. and .beta. parameters obtained from the beta -distribution fitting are related to sphericity and shape uniformity of the particles. Water content results for CDs, obtained by loss on drying at 160.degree. and Karl Fisher methods, yielded similar results; thus, it was possible to evap. practically all the water at 160.degree.. Water content of CDs 'as received' was dependent on the storage history of the samples after manufg. The DSC profiles of the CDs showed a broad, intense endothermic effect in the range 20-130.degree., this asym. peak was ascribed to water removal. .alpha.CD showed a characteristic peak with an onset temp. 138.degree.. This peak seems to be independent of water content, and only small modifications are obsd. after drying at high temp. Thus, a feasible structural change is assocd. with this peak.

L7 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:693103 HCAPLUS  
DOCUMENT NUMBER: 126:79822  
TITLE: Characterization and in vitro dissolution behavior of ketoconazole/.beta.- and 2-hydroxypropyl-.beta.- cyclodextrin inclusion compounds  
AUTHOR(S): Esclusa-Diaz, M. T.; Guimaraens-Mendez, M.; Perez-Marcos, M. B.; Vila-Jato, J. L.; Torres-Labandeira, J. J.  
CORPORATE SOURCE: Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Campus Universitario Sur, E-15706, Santiago de Compostela, Spain  
SOURCE: International Journal of Pharmaceutics (1996), 143(2), 203-210  
CODEN: IJPHDE; ISSN: 0378-5173  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effect of .beta.-cyclodextrin and 2-hydroxypropyl-.beta.-cyclodextrin on the soly. of ketoconazole in different media were studied. A type AL soly. diagram was obtained for ketoconazole and the two cyclodextrins in buffer soln., pH 5 and pH 6. The stability const. between ketoconazole and the two cyclodextrins were calcd. from the phase soly. diagrams. Increased ionization of the imidazole deriv. decreased the values of the stability const. The formation of solid inclusion complexes were exptl. prepd. by the kneading and spray-drying techniques. In order to confirm solid complex formation, X-ray diffractometry and differential scanning calorimetry were used. It was found that the spray-drying technique could be used to prep. the amorphous state of drug inclusion complexes. The dissoln. rates of ketoconazole from the inclusion complex made by spray-drying were faster than the pure drug, kneading systems and the phys. mixts. of drug and cyclodextrins. The enhanced dissoln. rate of spray-dried products might be attributed to the decreased particle size, the high-energetic amorphous state and inclusion complex formation.

```
=> d stat que
L1      267 SEA FILE=REGISTRY CYCLODEXTRIN?(L) BETA(L) HYDROXYPROPYL?
L2      23002 SEA FILE=REGISTRY CYCLODEXTRIN/BI
L3      22504 SEA FILE=HCAPLUS CYCLODEXTRIN? OR L2
L4      2089 SEA FILE=HCAPLUS L1 OR HYDROXYPROPYL?(L) BETA(L) CYCLODEXTRIN?
L5      703 SEA FILE=HCAPLUS L4 (L) (PREP? OR PROD? OR MANUF? OR PROCESS?)
L6      102 SEA FILE=HCAPLUS L5 (L) (DRI? OR DRY?)
L7      4 SEA FILE=HCAPLUS L6 AND PARTIC?(W) SIZE?
L8      2 SEA FILE=HCAPLUS (L3 OR L4) AND DRUM?(5A) (DRY? OR DRI?)
L9      2 SEA FILE=HCAPLUS L8 NOT L7
```

=> d ibib abs hitrn 19 1-2

L9 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:89870 HCAPLUS  
 DOCUMENT NUMBER: 136:139863  
 TITLE: Improved oral dosage formulations of  
 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea  
 INVENTOR(S): Cappola, Michael L.; Gereg, George W.; Way, Susan  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007772	A2	20020131	WO 2001-US21860	20010711

W: CA, JP, MX  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, TR

US 2002031544 A1 20020314 US 2001-902822 20010711  
 PRIORITY APPLN. INFO.: US 2000-220387P P 20000724

AB A process for prepg. improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea (Birb 796) (I) (I), with anti-inflammatory properties. Granulation of I within specified ranges provides improved dissoln. of the drug and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aq. sol. inclusion compd. capable of forming a complex with I, such as .beta.-cyclodextrin provides enhanced stability of the drug, in particular in highly ionic environments. Chipping and disintegration of tablets contg. >10% .beta.-cyclodextrin can be prevented by applying a polymeric coat to the surface of the tablet at <40.degree.. BIRB 796, lactose monohydrate, and povidone were **dry** mixed in a **drum** mixer for 5 min. The resulting dry mix was then granulated in a shear mixer with water. The wet granules were then spread onto stainless steel trays and dried in an oven at 40-50.degree. to an LOD of 2%. The dried granules were then milled through an 18-mesh screen in a cone mill. Microcryst. cellulose, pregelatinized starch, sodium starch glycolate, and colloidal silicon dioxide were then screened through an 18-mesh screen into the milled granules and the resulting mixt. mixed in a drum mixer for 12 min at approx. 30 rpm. Magnesium stearate, a lubricant, was then pre-blended with some of the mixed blend, screened through an 18 mesh screen and returned to the drum to be mixed an addnl. 4 min under the same conditions. The resulting blend was then tabletted using tablet tooling and adjusting the tablet wt. for the appropriate potency. After the blend was compressed into core tablets, the tablets were film coated. Tablets were coated to a wt. increase of 2-3%.

IT 7585-39-9, .beta.-Cyclodextrin 12619-70-4,

**Cyclodextrin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral dosage formulations of (butyltolylpyrazolyl)-  
 (morpholinylethoxy)naphthalenyl)urea)

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:194550 HCAPLUS

DOCUMENT NUMBER: 126:226730

TITLE: **Cyclodextrins** in fabric care consumer products

AUTHOR(S): Trinh, Toan

CORPORATE SOURCE: The Procter and Gamble Company, Sharon Woods Technical Center, Cincinnati, OH, 45241, USA

SOURCE: Proc. Int. Symp. Cyclodextrins, 8th (1996), 541-546.  
 Editor(s): Szejtli, J.; Szenté, L. Kluwer: Dordrecht, Neth.

CODEN: 64CDAL

DOCUMENT TYPE: Conference

LANGUAGE: English

AB **Cyclodextrins** can be used to provide a long lasting freshness benefit on laundered fabrics. This benefit can be achieved by incorporating **cyclodextrin**/perfume complexes in granular detergents, in liq.-fabric softeners, and, most effectively, in

dryer-added fabric softeners. Such dryer-added fabric softener products are com. available, and provide perfume benefits, such as in-wear long-lasting fabric freshness and in-use perfume blooming, that are recognized and appreciated by the consumer.

IT 12619-70-4, Cyclodextrin

RL: NUU (Other use, unclassified); USES (Uses)  
 (-perfume complex; **cyclodextrin**-perfume complexes in  
 dryer-added softeners for laundered fabric care)

=> d stat que

L1 267 SEA FILE=REGISTRY CYCLODEXTRIN?(L)BETA(L)HYDROXYPROPYL?  
 L2 23002 SEA FILE=REGISTRY CYCLODEXTRIN/BI  
 L3 22504 SEA FILE=HCAPLUS CYCLODEXTRIN? OR L2  
 L4 2089 SEA FILE=HCAPLUS L1 OR HYDROXYPROPYL?(L)BETA(L)CYCLODEXTRIN?  
 L5 703 SEA FILE=HCAPLUS L4 (L)(PREP? OR PROD? OR MANUF? OR PROCESS?)  
 L6 102 SEA FILE=HCAPLUS L5 (L)(DRI? OR DRY?)  
 L7 4 SEA FILE=HCAPLUS L6 AND PARTIC?(W)SIZE?  
 L8 2 SEA FILE=HCAPLUS (L3 OR L4) AND DRUM?(5A)(DRY? OR DRI?)  
 L9 2 SEA FILE=HCAPLUS L8 NOT L7  
 L10 61 SEA FILE=HCAPLUS L5 AND (AGGLOM? OR POWDER?)  
 L11 58 SEA FILE=HCAPLUS L10 NOT (L7 OR L9)  
 L12 2 SEA FILE=HCAPLUS L11 AND IMPROV?(5A)(DUST? OR SOLU?)  
 L13 2 SEA FILE=HCAPLUS L12 NOT (L7 OR L9)

=> d ibib abs hitrn l13 1-2

L13 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:505562 HCAPLUS

DOCUMENT NUMBER: 136:156300

TITLE: Improvement of the solubility and  
 absorption of econazole by hydrophilic cyclodextrins  
 AUTHOR(S): Nakanishi, Kunio; Nishi, Masatoshi; Masukawa, Tohru;  
 Ohta, Mituru

CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Setsunan  
 University, Hirakata Osaka, 573-0101, Japan

SOURCE: Cyclodextrin: From Basic Research to Market,  
 International Cyclodextrin Symposium, 10th, Ann Arbor,  
 MI, United States, May 21-24, 2000 (2000), 348-353.  
 Wacker Biochem Corp.: Adrian, Mich.  
 CODEN: 69BFYD

DOCUMENT TYPE: Conference; (computer optical disk)

LANGUAGE: English

AB .alpha.-, .beta.- And .gamma.-**cyclodextrin** (CyD) and .  
**beta.-cyclodextrin** derivs., monomethyl, 2,6-di-Me,  
 2,3,6-tri-Me, hydroxyethyl and **hydroxypropyl**, were used to form  
 a complex with econazole (ECZ). The hydrophilic CyD complex formation was  
 demonstrated by differential scanning calorimetry and **powder**  
 X-ray diffractometry. The soly. of ECZ with the hydrophilic CyD complexes  
 were significantly enhanced compared to econazole and glucose mixt. in  
 isotonic phosphate buffer pH 6.8. An increased plasma level of ECZ  
 following the hydrophilic CyD complexes administration was obsd. These  
 results indicate that the hydrophilic CyD complex may be useful as a

hydrophilic carrier in **preps.** of ECZ for oral and transdermal application.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:172599 HCAPLUS

DOCUMENT NUMBER: 130:213640

TITLE: New pharmaceutical compositions of meloxicam with **improved solubility** and bioavailability

INVENTOR(S): Struengmann, Andreas; Freudensprung, Brigitte; Klokckers, Karin

PATENT ASSIGNEE(S): Hexal A.-G., Germany

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909988	A1	19990304	WO 1998-EP5456	19980827
W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
CA 2301304	AA	19990304	CA 1998-2301304	19980827
AU 9894374	A1	19990316	AU 1998-94374	19980827
ZA 9807800	A	19990609	ZA 1998-7800	19980827
EP 1007049	A1	20000614	EP 1998-947467	19980827
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
BR 9812018	A	20000926	BR 1998-12018	19980827
JP 2001513563	T2	20010904	JP 2000-507378	19980827
US 6284269	B1	20010904	US 2000-486463	20000510

PRIORITY APPLN. INFO.: EP 1997-114816 A 19970827

WO 1998-EP5456 W 19980827

AB Pharmaceutical compns. contg. enolic carboxamide type antiinflammatory agent meloxicam that exhibit improved wettability, aq. soly., dissoln. behavior over a broad range of pH, and that are **prepd.** by crystal structure modification of the drug through dry or wet mech. homogenization with two further components - one of them is selected from a group of oligo - and dissoln. improving, or alkalizing agent. The application of the formulations according to the present invention results in an improved bioavailability and effectiveness of meloxicam. Thus, 16 g **hydroxypropyl .beta.-cyclodextrin** was mixed with 1.8 g of meloxicam and the mixt. was then further co-milled for 3 h at 25.degree. to reach desired metastable phys. state. A hydrogel



formulation contained above powder 100.0, hydroxypropyl  
Me cellulose 21.0, propylene glycol 2500.0, PEG-7-glyceryl conconate  
300.0, iso-Pr alc. 500.0, and water 6385.0 mg.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

show files

File 155:MEDLINE(R) 1966-2002/Jun W3  
 File 5:Biosis Previews(R) 1969-2002/Jun W3  
     (c) 2002 BIOSIS  
 File 34:SciSearch(R) Cited Ref Sci 1990-2002/Jun W4  
     (c) 2002 Inst for Sci Info  
 File 35:Dissertation Abs Online 1861-2002/May  
     (c) 2002 ProQuest Info&Learning  
 File 51:Food Sci.&Tech.Abs 1969-2002/Jun W1  
     (c) 2002 FSTA IFIS Publishing  
 File 71:ELSEVIER BIOBASE 1994-2002/Jun W3  
     (c) 2002 Elsevier Science B.V.  
 File 73:EMBASE 1974-2002/Jun W3  
     (c) 2002 Elsevier Science B.V.  
 File 74:Int.Pharm.Abs. 1970-2002/Apr  
     (c) 2002 Amer.Soc.of Health-System Pharm.  
 File 76:Life Sciences Collection 1982-2002/Jun  
     (c) 2002 Cambridge Sci Abs  
 File 94:JICST-EPlus 1985-2002/Apr W4  
     (c)2002 Japan Science and Tech Corp(JST)  
 File 144:Pascal 1973-2002/Jun W3  
     (c) 2002 INIST/CNRS  
 File 148:Gale Group Trade & Industry DB 1976-2002/Jun 21  
     (c)2002 The Gale Group  
 File 172:EMBASE Alert 2002/Jun W3  
     (c) 2002 Elsevier Science B.V.  
 File 305:Analytical Abstracts 1980-2002/Jun W2  
     (c) 2002 Royal Soc Chemistry  
 File 342:Derwent Patents Citation Indx 1978-01/200162C  
     (c) 2002 Thomson Derwent  
 File 347:JAPIO Oct 1976-2002/Feb(Updated 020604)  
     (c) 2002 JPO & JAPIO  
 File 351:Derwent WPI 1963-2002/UD,UM &UP=200239  
     (c) 2002 Thomson Derwent  
 File 357:Derwent Biotech Res. 1982-2002/Mar W5  
     (c) 2002 Thomson Derwent & ISI  
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
     (c) 1998 Inst for Sci Info  
 File 440:Current Contents Search(R) 1990-2002/Jun 21  
     (c) 2002 Inst for Sci Info  
 ?set hilight on  
 HILIGHT set on as ' '  
 ?ds

Set	Items	Description
S1	3553	(CYCLODEXTRIN? OR HYDROXYPROPYL(2W)CYCLODEXTRIN?) AND (DRY? OR DRIED)
S2	2390	RD (unique items)
S3	989	S2 AND (POWD? OR PARTIC? OR DUST?)
S4	22	S3 AND AGGLOM?

?t4/3 ab/1-22

>>>No matching display code(s) found in file(s): 342

4/AB/1 (Item 1 from file: 148)  
 DIALOG(R)File 148:Gale Group Trade & Industry DB  
 (c)2002 The Gale Group. All rts. reserv.

11743374 SUPPLIER NUMBER: 59329283 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
 Additives for Fabric Care.(Brief Article)  
 Boswell, Clay  
 Chemical Market Reporter, 257, 4, FR 17

Jan 24, 2000  
DOCUMENT TYPE: Brief Article ISSN: 1092-0110 LANGUAGE: English  
RECORD TYPE: Fulltext  
WORD COUNT: 2148 LINE COUNT: 00176

4/AB/2 (Item 2 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

11564377 SUPPLIER NUMBER: 57578869 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
The 1999 FOOD PROCESSING AWARDS.  
Food Processing, 60, 10, 20  
Oct, 1999  
ISSN: 0015-6523 LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 7075 LINE COUNT: 00604

4/AB/3 (Item 3 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

10810742 SUPPLIER NUMBER: 53864285 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Facial skin care: Cleansers move forward.  
BRANNA, TOM  
European Cosmetic Markets, 16, 2, 57(1)  
Feb, 1999  
ISSN: 0957-1515 LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 11949 LINE COUNT: 01079

4/AB/4 (Item 4 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

10337047 SUPPLIER NUMBER: 20939857 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Colour innovations aid the formulator.(new ingredients for cosmetics)  
Woodruff, John  
Manufacturing Chemist, v69, n6, p15(1)  
June, 1998  
ISSN: 0262-4230 LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 1999 LINE COUNT: 00185

4/AB/5 (Item 5 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

09827835 SUPPLIER NUMBER: 16962551 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Skin care and treatment.(Advances in Cosmetic Science and Technology, Part  
4)  
Fox, Charles  
Cosmetics and Toiletries, v110, n5, p63(24)  
May, 1995  
ISSN: 0361-4387 LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 15336 LINE COUNT: 01413

4/AB/6 (Item 6 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

07294520 SUPPLIER NUMBER: 15421052 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Exploring the 1994 IFT Food Expo. (exhibition preview)  
Kevin, Kitty  
Food Processing, v55, n5, p92(24)  
May, 1994  
ISSN: 0015-6523 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 11609 LINE COUNT: 01011

ABSTRACT: A preview of the 1994 IFT Food Expo, to run Jun 26-29, 1994, is provided. The exhibition will showcase more health-oriented products than in the past, including fortified, vitamin and mineral-enriched foods. New food processing technologies will also be in evidence. An alphabetized list of exhibitors, together with product summaries, is provided.

4/AB/7 (Item 7 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

06734112 SUPPLIER NUMBER: 14529935 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Food and Dairy Expo '93 marches to Atlanta. (Atlanta, Georgia)(includes list of selected exhibitors) (Food Manufacturing & Packaging)  
Prepared Foods, v162, n10, p100(16)  
Sept, 1993  
ISSN: 0747-2536 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 6503 LINE COUNT: 00559

ABSTRACT: The Food & Dairy Expo '93 will be held on Oct 16-19, 1993 at the Georgia World Congress Center in Atlanta, GA. An estimated 18,000 food industry executives, professionals and personnel from all over the world are expected to attend the show. 500 exhibitors will showcase their wares in a space spread of 25,000 sq ft. Some of the wares to be displayed include developments in packaging machinery and materials, transportation, ingredients, control systems, sanitary services and instrumentation.

4/AB/8 (Item 8 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

06698877 SUPPLIER NUMBER: 14379457 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
The near future of tablet excipients.  
Reimerdes, D.  
Manufacturing Chemist, v64, n7, p14(2)  
July, 1993  
ISSN: 0262-4230 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT  
WORD COUNT: 2023 LINE COUNT: 00186

4/AB/9 (Item 9 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

06217190 SUPPLIER NUMBER: 13588601 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Seasoning solution in capsule form. (encapsulation techniques for food flavoring)  
O'Donnell, Claudia D.  
Prepared Foods, v161, n10, p71(2)  
Sept, 1992  
ISSN: 0747-2536 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT

WORD COUNT: 1311 LINE COUNT: 00113

4/AB/10 (Item 10 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

04896813 SUPPLIER NUMBER: 09297396 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
IFSCC: cosmetic science beyond the 1990s. (part 2) (International  
Federation of the Societies of Cosmetic Chemists)  
Christiansen, Suzanne; Shaw, Anita Hipius  
Soap-Cosmetics-Chemical Specialties, v66, n12, p42(7)  
Dec, 1990  
ISSN: 0091-1372 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT  
WORD COUNT: 5220 LINE COUNT: 00427

4/AB/11 (Item 11 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2002 The Gale Group. All rts. reserv.

04124490 SUPPLIER NUMBER: 08026847 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Flavor research aimed at delivery.  
Przybyla, Ann E.  
Food Engineering, v61, n8, p123(4)  
August, 1989  
ISSN: 0193-323X LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT  
WORD COUNT: 2380 LINE COUNT: 00196

4/AB/12 (Item 1 from file: 347)  
DIALOG(R)File 347:JAPIO  
(c) 2002 JPO & JAPIO. All rts. reserv.

01916119  
MECLOFENOXATE HYDROCHLORIDE COMPOSITION

PUB. NO.: 61-130219 [JP 61130219 A]  
PUBLISHED: June 18, 1986 (19860618)  
INVENTOR(s): TANAKA TERUKAZU  
KAGAMI IZUMI  
KOBIKI MITSUAKI  
IMAZATO TAKESHI  
APPLICANT(s): DAINIPPON PHARMACEUT CO LTD [000291] (A Japanese Company or  
Corporation), JP (Japan)  
APPL. NO.: 59-254410 [JP 84254410]  
FILED: November 30, 1984 (19841130)  
JOURNAL: Section: C, Section No. 381, Vol. 10, No. 318, Pg. 139,  
October 29, 1986 (19861029)

#### ABSTRACT

PURPOSE: To provide the titled composition having remarkably mitigated bitter taste, resistant to moisture-absorption, agglomeration, deliquescence, and hydrolysis, administrable in the form of powder, etc., and applicable at continuously adjustable dose, by compounding meclofenoxate hydrochloride with a cyclodextrin.

CONSTITUTION: The objective composition contains meclofenoxate hydrochloride, a cyclodextrin and if necessary other additives. The cyclodextrin is especially preferably .beta.- cyclodextrin, and the amount is more than equimolar, preferably large excess to the meclofenoxate

hydrochloride used as a main drug component. The inclusion is preferably carried out by the fluidized layer granulation method, by blowing dry air to as mixture of meclofenoxate hydrochloride and cyclodextrin from the bottom to effect the floatation of the mixture, and spraying water to the floating mixture from the top. The titled composition is used preferably in the form of powder, granule, or dry syrup.

4/AB/13 (Item 1 from file: 351)  
 DIALOG(R) File 351:Derwent WPI  
 (c) 2002 Thomson Derwent. All rts. reserv.

014494632

WPI Acc No: 2002-315335/200235

XRAM Acc No: C02-091743

XRPX Acc No: N02-246822

Preparing an electrostatically chargeable electro- powder useful for electrostatic charging and dosing for functionality in a dry powder inhaler device by addition of a powder to a mixture of excipient and active ingredient

Patent Assignee: MICRODRUG AG (MICR-N)

Inventor: NILSSON L; NILSSON T

Number of Countries: 096 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200211803	A1	20020214	WO 2001SE1682	A	20010727	200235 B
SE 200002822	A	20020129	SE 20002822	A	20000804	200235

Priority Applications (No Type Date): SE 20002822 A 20000804

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200211803 A1 E 54 A61M-015/00

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

SE 200002822 A A61M-015/00

Abstract (Basic): WO 200211803 A1

Abstract (Basic):

NOVELTY - Preparation of an electro- powder involves analyzing a formulation containing an electrostatically chargeable powder, an active agent and optionally excipient for determining its electrostatic qualities; preparing a formulation (a) in accordance with the analysis results using a selected formulation and manufacturing equipment; analyzing the prepared (a) to verify the basic requirements of the finely-divided electrostatically chargeable electro- powder.

DETAILED DESCRIPTION - Method (I) of preparation of an electro- powder having a finely-divided powder involves: i) providing a first electrostatically chargeable powder (A) having a particle size suitable for inhalation therapy and consisting an active agent or the mixture of the agent and optionally at least one excipients; (ii) analyzing the pharmaceutical formulation for determining its electrostatic qualities for selecting a composition and manufacturing process giving suitable electrostatic properties; iii) preparing a formulation (a) in accordance with the analysis results using a selected formulation and a manufacturing equipment; iii) analyzing the prepared (a) to verify that it fulfils the basic requirements of a finely-divided electrostatically chargeable electro- powder suitable

for manufacture of doses. If the formulation is found not to comply with the basic requirements, the above process is repeated for finding another composition and/or manufacturing process for a suitable new formulation.

INDEPENDENT CLAIMS are also included for the following:

(1) a finely divided electrostatically chargeable electropowder for manufacture of doses using either corona, induction or tribo-electric charging in conjunction with electric field dosing techniques and for administration into the airways by oral inhalation from a dry powder inhaler, contains particles (A1) having aerodynamic mass median diameter of at most 5µm and providing electrostatic properties regarding absolute specific charge per mass after charging of 0.1 - 50 (preferably 0.1 - 25) µC/g and presenting a charge decay rate constant (Q50) of more than 0.1 seconds;

(2) a method (II) for preparing (A) involving adding at least one excipient to at least one active ingredient forming the powder to improve the efficiency of the powder ;

(3) preparing an electrostatically chargeable electro- powder to achieve specified electrostatic properties involving dosing the eletro- powder onto a technical device using electric field dosing techniques and subsequently loading into an dry powder inhaler device the technical device containing at least one doses of powder .

USE - For manufacture of doses using either corona, induction or tribo-electric charging in conjunction with electric field dosing techniques of the powder intended for administration into the airways by oral inhalation from a dry powder inhaler device.

ADVANTAGE - The electro- powder can be dosed with high efficacy and quality by electrostatic dosing equipment. The powder provides electrostatic properties regarding absolute specific charge per mass after charging of 0.1 - 25 µC/g.

pp; 54 DwgNo 0/13

4/AB/14 (Item 2 from file: 351)  
DIALOG(R)File 351:Derwent WPI  
(c) 2002 Thomson Derwent. All rts. reserv.

014180148

WPI Acc No: 2002-000845/200201

XRAM Acc No: C02-000410

XRPX Acc No: N02-000626

Ink jet recording material comprising substrate, and ink receiving layer comprising binder and fine particles of pigment(s) from silica, aluminosilicate, alpha-, theta-, delta- or gamma-aluminas

Patent Assignee: OJI PAPER CO (OJIP )

Inventor: ENDO E; KITAMURA R; MUKOYOSHI S; OSHIMA K; TAKAHASHI T; TSUCHIDA T; OHSHIMA K

Number of Countries: 028 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 1120281	A1	20010801	EP 2001300682	A	20010125	200201 B
JP 2001277712	A	20011010	JP 2000280504	A	20000914	200201
US 20010016249	A1	20010823	US 2001769318	A	20010126	200201
JP 2001341412	A	20011211	JP 2000280557	A	20000914	200213

Priority Applications (No Type Date): JP 2000280557 A 20000914; JP 200019758 A 20000128; JP 200086939 A 20000327; JP 2000280504 A 20000914

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 1120281	A1	E	60	B41M-005/00	

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT

LI LT LU LV MC MK NL PT RO SE SI TR  
 JP 2001277712 A 23 B41M-005/00  
 US 20010016249 A1 B41M-005/00  
 JP 2001341412 A 23 B41M-005/00

Abstract (Basic): EP 1120281 A1

Abstract (Basic):

NOVELTY - An ink jet recording material has a substrate, and an image-recording stratum on at least one surface of the substrate. The stratum is formed from ink receiving layer(s) comprising a binder and pigment particles dispersed in the binder. The fine particles of pigment(s) comprise silica, aluminosilicate, alpha, theta, delta or gamma-aluminas and having an average particle size of at most 1.

USE - For recording ink images.

ADVANTAGE - The invention can record ink images having high color density, clarity, water resistance moisture resistance, and resistance to blotting of the ink. It has a high surface smoothness and a satisfactory gloss. The recorded ink images are comparable in sharpness and clarity to the silver-salt type photographic images.

pp; 60 DwgNo 0/3

4/AB/15 (Item 3 from file: 351)  
 DIALOG(R) File 351: Derwent WPI  
 (c) 2002 Thomson Derwent. All rts. reserv.

013948611

WPI Acc No: 2001-432825/200146

XRAM Acc No: C01-130953

Formation of cyclodextrin-guest complex, for use in foods and pharmaceuticals, involves mixing water and emulsifying agent with complex of cyclodextrin and guest molecule, to form a uniform dispersion

Patent Assignee: CERESTAR HOLDING BV (CERE-N)

Inventor: QI H; SHIEH W; XU A

Number of Countries: 021 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200148024	A1	20010705	WO 2000IB2060	A	20001220	200146 B
EP 1155043	A1	20011121	EP 2000991302	A	20001220	200176
			WO 2000IB2060	A	20001220	

Priority Applications (No Type Date): US 2000686695 A 20001011; US 99172099  
 P 19991223

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 200148024	A1	E	26	C08B-037/16	

Designated States (National): JP

Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LU  
 MC NL PT SE TR

EP 1155043 A1 E C08B-037/16 Based on patent WO 200148024

Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LI  
 LU MC NL PT SE TR

Abstract (Basic): WO 200148024 A1

Abstract (Basic):

NOVELTY - Forming a cyclodextrin-guest complex, comprising mixing water and emulsifying agent with complex of cyclodextrin and guest molecule, to form a uniform dispersion, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for cyclodextrin-guest complex obtained by the novel method. The complex is a dry particulate encapsulated by emulsifying agent.



USE - For use in foods, pharmaceuticals, cosmetics, agricultural and chemical fields for delivering guest molecules.

ADVANTAGE - The use of emulsifying agent during the complex formation of cyclodextrin and guest molecule, complex agglomerate which is smooth, stable and uniform in distribution is obtained. The water solubility of beta cyclodextrin is increased without any chemical modification.

pp; 26 DwgNo 0/0

4/AB/16 (Item 4 from file: 351)  
DIALOG(R)File 351:Derwent WPI  
(c) 2002 Thomson Derwent. All rts. reserv.

013816999

WPI Acc No: 2001-301211/200132

XRAM Acc No: C01-092621

XRPX Acc No: N01-216156

Absorbent, crosslinked polymer, used as absorber aqueous liquid, e.g. body fluids, packaging material, plant culture, soil improver or carrier, contains bound or enclosed cyclodextrin (derivative) and silicon-rich zeolite

Patent Assignee: STOCKHAUSEN GMBH & CO KG (CHFS )  
Inventor: BREHM H; HARREN J; ISSBERNER J; MERTENS R

Number of Countries: 094 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
DE 19939662	A1	20010222	DE 1039662	A	19990820	200132 B
WO 200113841	A1	20010301	WO 2000EP7741	A	20000809	200132
AU 200069942	A	20010319	AU 200069942	A	20000809	200136

Priority Applications (No Type Date): DE 1039662 A 19990820

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

DE 19939662 A1 15 C08L-005/16

WO 200113841 A1 G A61F-013/15

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

AU 200069942 A A61F-013/15 Based on patent WO 200113841

Abstract (Basic): DE 19939662 A1

Abstract (Basic):

NOVELTY - Absorbent, crosslinked polymer for water or aqueous body fluids, based on monoethylenically unsaturated monomers with optionally partly neutralized acid group, contains a cyclodextrin (derivative) (I) and silicon-rich zeolite (II), at least partly in covalently or ionically bound or enclosed form.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the production of the polymer.

USE - The polymer is use for improved absorption of odors from body fluids; as absorbent for aqueous liquids, preferably in the construction of (un)foamed sheets for absorbing body fluids, packaging materials, for cultivating plants and as soil improvers; in hygiene articles; and as carrier and/or stabilizer for active materials, e.g. fertilizers and other agent, optionally with retarded release (all claimed).

ADVANTAGE - The polymer reduces odor emissions considerably. The

odor-binding substance is very uniformly distributed, unmixing before and during use is minimized and the amount required is very small. The absorbent has good retention and swelling properties under pressure. In the production of the polymer, problems associated with mixing dry substances of different particle size, e.g. granulates and powders, and agglomeration are avoided and no dust is formed.

pp; 15 DwgNo 0/0

4/AB/17 (Item 5 from file: 351)  
 DIALOG(R) File 351:Derwent WPI  
 (c) 2002 Thomson Derwent. All rts. reserv.

013708850

WPI Acc No: 2001-193074/200120

XRAM Acc No: C01-058033

Manufacture of particles of reaction product of amine with aldehyde or ketone, useful for delivering fragrance in laundry, hard surface and personal cleaning compositions, involves mixing with carrier of low melting point

Patent Assignee: PROCTER & GAMBLE CO (PROC )

Inventor: BUSCH A; HOMBLE M; LAUDAMIEL C; SMETS J; TRUJILLO R; WEVERS J

Number of Countries: 095 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 1067173	A1	20010110	EP 99870146	A	19990708	200120 B
WO 200104247	A1	20010118	WO 2000US18468	A	20000706	200120
AU 200059160	A	20010130	AU 200059160	A	20000706	200127

Priority Applications (No Type Date): EP 99870146 A 19990708

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 1067173	A1	E	53	C11D-003/00	

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT  
 LI LT LU LV MC MK NL PT RO SE SI

WO 200104247	A1	E	C11D-003/00
--------------	----	---	-------------

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA  
 CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP  
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT  
 RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
 IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

AU 200059160	A	C11D-003/00	Based on patent WO 200104247
--------------	---	-------------	------------------------------

Abstract (Basic): EP 1067173 A1

Abstract (Basic):

NOVELTY - Manufacture of particles of the reaction product of (i) a compound containing a primary and/or secondary amine functional group with (ii) an active ketone or aldehyde compound involves mixing the reaction product with a carrier of melting point less than 30 deg. C.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) The processed amine reaction product.
- (2) A method of incorporating the amine reaction product into finished products, preferably by spraying and/or dry -addition.
- (3) A composition comprising laundry or cleaning ingredient(s) and the processed amine reaction product.
- (4) A method for delivering residual active to a surface by contacting it with the processed reaction product (or composition) and then treating it with a material so that the active is released.

USE - The composition is used in laundry, hard surface and personal cleaning compositions, especially for delivering residual fragrance and

fabric care onto fabrics (all claimed).

ADVANTAGE - The amine reaction product can be easily formulated into compositions. It exhibits better deposition and longer lasting release than an untreated product.

pp; 53 DwgNo 0/0

4/AB/18 (Item 6 from file: 351)  
DIALOG(R) File 351:Derwent WPI  
(c) 2002 Thomson Derwent. All rts. reserv.

013663060

WPI Acc No: 2001-147272/200115

XRAM Acc No: C01-043587

Particles with a perfectly smooth surface and having a specified median diameter and surface rugosity are prepared by treatment with a high speed mixer-granulator, useful as carriers in inhalation powder mixtures with micronized drugs

Patent Assignee: CHIESI FARM SPA (CHIE-N)

Inventor: BETTINI R; CAPONETTI G; CATELLANI P L; COLOMBO P; VENTURA P

Number of Countries: 092 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200105429	A2	20010125	WO 2000EP6690	A	20000713	200115 B
AU 200068232	A	20010205	AU 200068232	A	20000713	200128
EP 1196146	A2	20020417	EP 2000956180	A	20000713	200233
			WO 2000EP6690	A	20000713	

Priority Applications (No Type Date): IT 99MI1582 A 19990716

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200105429 A2 E 39 A61K-047/00

Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

AU 200068232 A A61K-047/00 Based on patent WO 200105429

EP 1196146 A2 E A61K-009/14 Based on patent WO 200105429

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

Abstract (Basic): WO 200105429 A2

Abstract (Basic):

NOVELTY - Carrier particles for use in powdery mixtures for inhalation of micronized drugs via dry powder inhalers, have a smooth surface and are prepared by treatment with a high speed mixer-granulator.

DETAILED DESCRIPTION - Carrier particles for use in formulations for pulmonary administration of micronized drugs via a powder inhaler have median diameter greater than 90  $\mu$ m and surface rugosity at most 1.

INDEPENDENT CLAIMS are also included for the following:

(a) preparation of smooth carrier particles where smoothing of the particles is accomplished using a high speed granulator after repeated stages of wetting with a solvent and drying ;

(b) preparation of a pharmaceutical formulation by adding 1 or more active ingredients having particles with median diameter at most 6.4  $\mu$ m to the carrier prepared as above;

(c) pharmaceutical compositions for inhalation, obtained by mixing

active principles in the form of micronized powder with particles as above.

USE - For administration of drugs by inhalation, particularly drugs for the treatment of respiratory diseases such as beta-agonists (e.g. salbutamol, formoterol, salmeterol and terbutaline), antiinflammatory steroids (e.g. beclometasone dipropionate, flunisolide and budesonide) or an anticholinergic (e.g. ipratropium bromide or oxitropium bromide). Any active ingredient suitable for endobronchial administration may be used.

ADVANTAGE - The method makes the surface of the particles of the carrier smooth, without any roughness or hollows, clefts and sharp edges, which represent sites of high surface energy to which the drug particles might adhere. The method permits improvement of the uniformity of the surface characteristics of commercially available substances commonly employed as carriers for inhalation powders, whose characteristics are generally variable. The particles of the additive are not released from the carrier particles during inhalation and so do not reach the smaller branching of the pulmonary tree. Powders for inhalation obtained by mixing the smooth carrier particles (with or without coating) with a micronized drug give rise to a particularly high respirable fraction of drug. The method is rapid and convenient and allows smooth particles to be obtained starting from an industrial powder consisting of rough particles without substantially altering their average size and geometry. The use of the high speed mixer-granulator allows the surface characteristics and shape of particles of pharmaceutical excipients to be altered without agglomerating them and without significantly changing their crystalline structure and physicochemical properties. The process only gives rise to a slight reduction of the particle size relevant to the starting product, without increasing the fraction of fine particles. The process also eliminates fine particles present in the original powder.

pp; 39 DwgNo 0/3

4/AB/19 (Item 7 from file: 351)  
 DIALOG(R)File 351:Derwent WPI  
 (c) 2002 Thomson Derwent. All rts. reserv.

013099338

WPI Acc No: 2000-271210/200023

XRAM Acc No: C00-082720

Quick release pharmaceutical composition for oral administration useful for treatment of acute and/or mild or moderate pain

Patent Assignee: NYCOMED DANMARK AS (NYCO-N)

Inventor: BERTELSEN P; HANSEN N G V; ITAI S; RUCKENDORFER H; HANSEN N G

Number of Countries: 088 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200015195	A1	20000323	WO 99DK480	A	19990910	200023 B
AU 9955045	A	20000403	AU 9955045	A	19990910	200034
EP 1109534	A1	20010627	EP 99941418	A	19990910	200137
			WO 99DK480	A	19990910	

Priority Applications (No Type Date): DK 981143 A 19980910

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200015195 A1 E 88 A61K-009/16

Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN  
 CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI

SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW

AU 9955045 A A61K-009/16 Based on patent WO 200015195

EP 1109534 A1 E A61K-009/16 Based on patent WO 200015195

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT  
LI LT LU LV MC MK NL PT RO SE SI

Abstract (Basic): WO 200015195 A1

Abstract (Basic):

NOVELTY - A quick release pharmaceutical composition for oral administration comprises a therapeutically and/or prophylactically active substance which has a solubility of at most about 0.1% weight/volume in 0.1N hydrochloric acid at room temperature.

DETAILED DESCRIPTION - The composition is based on a powder comprising the active substance. The powder has a particle size such that when subjected to a sieve analysis at least about 90%-99% passes through a 180 mum. sieve. The powder is contacted with an aqueous medium to form a particulate composition which has a particle size such that when subjected to a sieve analysis at least about 50%-95%, passes through a 180 mum sieve. When tested by a dissolution method using 0.07N hydrochloric acid as the dissolution medium the composition releases at least about 50% weight/weight of the active substance within the first 20 minutes of the test.

USE - The composition is useful for treatment and/or prophylaxis of acute and/or mild or moderate pain, particularly for fast relief of acute pain.

pp; 88 DwgNo 0/3

4/AB/20 (Item 8 from file: 351)

DIALOG(R) File 351:Derwent WPI

(c) 2002 Thomson Derwent. All rts. reserv.

013099308

WPI Acc No: 2000-271180/200023

XRAM Acc No: C00-082691

Use of cyclodextrin to stabilize

N-(N-(3,3-dimethylbutyl)-1-alpha-aspartyl)-L-phenyl alanine-1-methyl ester

Patent Assignee: NUTRASWEET CO (NUTR-N)

Inventor: BISHAY I E; CLEARY M; DESAI N; FOTOS J G; SCHROEDER S

Number of Countries: 089 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200015049	A1	20000323	WO 99US21471	A	19990916	200023 B
AU 9961504	A	20000403	AU 9961504	A	19990916	200034

Priority Applications (No Type Date): US 98100867 P 19980917

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200015049 A1 E 46 A23L-001/236

Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN  
CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

AU 9961504 A A23L-001/236 Based on patent WO 200015049

Abstract (Basic): WO 200015049 A1

## Abstract (Basic):

NOVELTY - A sweetener composition comprises N-(N-(3,3-dimethyl-butyl)-L-alpha-aspartyl)-L-phenyl alanine 1-methyl ester and cyclodextrin .

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a process for stabilizing a sweetener composition comprising contacting cyclodextrin with N-(N-(3,3-dimethylbutyl)-L-alpha-aspartyl)-L-phenyl alanine-1-methyl ester (I) to form a mixture.

USE - The compositions are suitable for use in any food to replace natural sweeteners, as well as other high intensity sweeteners, normally used as sweeteners. The composition can be used for sweetening a beverage (such as carbonated soft drinks, powdered soft drinks, coffees, teas, juices, sweetened and flavoured waters, sport/energy/health drinks, alcoholic beverages, beverages processed with heating and hot-filled packaging and cold-filled beverages), a fluid dairy product (such as non-frozen, partially frozen and frozen milks, ice creams, sorbets and yogurts), a condiment (such as ketchup, mayonnaise, salad dressing, Worcestershire sauce, tomato sauce, chilli sauce and mustard), a baked good (such as cakes, cookies, pastries, breads and donuts), a frosting, a baking filling (such as a low or neutral pH filling, a high, medium or low solids filling, a fruit or milk based filling, a hot or cold make-up filling or a non-fat to full-fat filling), a candy or chewing gum or a table-top sweetener (claimed).

ADVANTAGE - The compositions are effective for enhancing the stability of (I) in the foods and beverages which are canned, bottled, pouched, packaged or packed in manners suitable for shipping and display at room temperature or in a chilled state.

pp; 46 DwgNo 0/0

4/AB/21 (Item 9 from file: 351)  
DIALOG(R)File 351:Derwent WPI  
(c) 2002 Thomson Derwent. All rts. reserv.

010065458

WPI Acc No: 1994-333170/199441

XRAM Acc No: C94-151604

Solid dryer -activated fabric conditioning compsn - comprises uncomplexed cyclodextrin of particle size in sufficient amts to absorb and control odour, useful for detergent compsns, flat woven fabrics

Patent Assignee: PROCTER & GAMBLE CO (PROC )

Inventor: TORDIL H B; TRINH T; TORDIL H

Number of Countries: 021 Number of Patents: 009

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9422999	A1	19941013	WO 94US2858	A	19940317	199441 B
EP 692014	A1	19960117	EP 94912795	A	19940317	199608
			WO 94US2858	A	19940317	
JP 8508547	W	19960910	JP 94522111	A	19940317	199704
			WO 94US2858	A	19940317	
US 5681806	A	19971028	US 9340703	A	19930331	199749
			US 94278703	A	19940721	
			US 96590711	A	19960124	
US 5773408	A	19980630	US 9340703	A	19930331	199833
			US 94278703	A	19940721	
			US 96590711	A	19960124	
			US 97840527	A	19970422	
US 5783552	A	19980721	US 9340703	A	19930331	199836
			US 94278703	A	19940721	

			US 96590711	A	19960124	
			US 97851758	A	19970506	
EP 692014	B1	19980826	EP 94912795	A	19940317	199838
			WO 94US2858	A	19940317	
DE 69412802	E	19981001	DE 612802	A	19940317	199845
			EP 94912795	A	19940317	
			WO 94US2858	A	19940317	
CA 2157566	C	19990615	CA 2157566	A	19940317	199942
			WO 94US2858	A	19940317	

Priority Applications (No Type Date): US 9340703 A 19930331; US 94278703 A 19940721; US 96590711 A 19960124; US 97840527 A 19970422; US 97851758 A 19970506

#### Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

WO 9422999	A1	E	35	C11D-003/00	
------------	----	---	----	-------------	--

Designated States (National): BR CA JP

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

EP 692014	A1	E		C11D-003/00	Based on patent WO 9422999
-----------	----	---	--	-------------	----------------------------

Designated States (Regional): AT BE CH DE FR GB IE IT LI LU NL SE

JP 8508547	W		37	D06M-015/11	Based on patent WO 9422999
------------	---	--	----	-------------	----------------------------

US 5681806	A		12	C11D-001/62	Cont of application US 9340703
------------	---	--	----	-------------	--------------------------------

Cont of application US 94278703

US 5773408	A			C11D-003/382	Cont of application US 9340703
------------	---	--	--	--------------	--------------------------------

Cont of application US 94278703

Div ex application US 96590711

Div ex patent US 5681806

US 5783552	A			C11D-003/22	Cont of application US 9340703
------------	---	--	--	-------------	--------------------------------

Cont of application US 94278703

Div ex application US 96590711

Div ex patent US 5681506

EP 692014	B1	E		C11D-003/00	Based on patent WO 9422999
-----------	----	---	--	-------------	----------------------------

Designated States (Regional): CH DE GB LI

DE 69412802	E			C11D-003/00	Based on patent EP 692014
-------------	---	--	--	-------------	---------------------------

Based on patent WO 9422999

CA 2157566	C	E		D06M-015/11	Based on patent WO 9422999
------------	---	---	--	-------------	----------------------------

#### Abstract (Basic): WO 9422999 A

Solid dryer -activated fabric conditioning compsn. comprises uncomplexed cyclodextrin of particle size less than 12 microns in an amt. sufficient to absorb and control odour.

Also claimed are (i) an article contg. the compsn.; (ii) a detergent compsn. contg. the compsn.; (iii) flat woven fabrics contg. the uncomplexed cyclodextrin; and (iv) a method of treating fabrics using the conditioning compsn.

The compsn. pref. comprises 10-95% of fabric softening agent. The cyclodextrin is selected from unsubstd. cyclodextrin contg. 6-12 glucose units and/or its derivs. The cyclodextrin is capable of forming inclusion complexes with odour cpds. At least a major portion of the cyclodextrin is selected from alpha, beta- and/or gamma-cyclodextrins (esp. beta- cyclodextrin). The compsn. additionally contains an inclusion complex of the cyclodextrin and perfume. A major portion of the perfume is selected from highly volatile and/or moderately volatile (esp. highly volatile perfume). The cyclodextrin and/or the inclusion complex have a particle size smaller than 8 (esp. 5) microns (esp. 0.001-10, more esp. 0.05-5 microns). Article comprises: the fabric softening compsn. contg. 30-95% fabric softening agent, uncomplexed cyclodextrin, opt. the inclusion complex and a dispensing means which provides for release of the compsn. to fabrics in an automatic laundry drier at operating temps. The amt. of

uncomplexed cyclodextrin is 5-70%, the inclusion complex 0.5-60% and the operating temp. is 35-115 deg.C. The granular detergent compsn. comprises the conditioning compsn. in the form of particles which survive the wash and adhere to fabric surfaces and comprises at least 10% of the fabric softening agent and effective amt. of the uncomplexed cyclodextrin .

USE/ADVANTAGE - Compsns. are pref. either in particulate form, compounded with other materials in solid form, e.g. tablets, pellets, agglomerates , etc. or attached to a substrate. The small particle size of cyclodextrin controls odours more effectively such as those of cigarette odour, underarm odour, etc.

Dwg.0/0

Abstract (Equivalent): US 5681806 A

Solid, dryer -activated fabric conditioning composition comprising from about 10% to about 95% of fabric softening agent selected from cationic and nonionic fabric softeners and mixtures of it and an effective amount, sufficient to absorb and control odour of uncomplexed cyclodextrin having a particle size of less than about 5 microns, the fabric treatment composition being flowable at dryer operating temperatures.

Dwg.0/0

4/AB/22 (Item 10 from file: 351)

DIALOG(R)File 351:Derwent WPI

(c) 2002 Thomson Derwent. All rts. reserv.

009761847

WPI Acc No: 1994-041698/199405

XRAM Acc No: C94-018844

Prodn. of powdered juice concentrate - involves adding mixt. of alpha, beta and gamma- cyclodextrin (s) to juice before concentrating

Patent Assignee: AS URALS SECT BASHKIR BIOL INST (AURB-R); KEMER FOOD IND TECHN INST (KEFO-R)

Inventor: ANGERSBAKH A K; ROMANOV A S; USANOV N G

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
SU 1787012	A3	19930107	SU 4909285	A	19910211	199405 B

Priority Applications (No Type Date): SU 4909285 A 19910211

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
SU 1787012	A3	4	A23L-002/02	

Abstract (Basic): SU 1787012 A

The method comprises concentrating juice, mixing it with castor sugar, drying and milling of obtd. mixt. and addn. of aromatising and colouring additives.

To improve biological value of juice concentrate and stability of its properties on storage, the mixt. of alpha-, beta- and gamma- cyclo-dextrins is added to juice before concentrating stage, in amt. 0.1-10.0 wt.%, and aromatising and colouring substances are added into concentrated juice in form of inclusion complexes with cyclodextrins , in amts. 0.2-20.0 wt.% and 0.02-20.0 wt.%, respectively. Concentrated juice, contg. aromatising and colouring additives, is then mixed with castor sugar and produced agglomerate is dried to moisture content 2.5% and milled to particle size 0.2 mm. Obtd. powdered concentrate can be used in prodn. of soft drinks, by dissolving 25g of concentrate in 200 g of water, or as component of recipes of confectionery articles.



Tests show that proposed method, compared to prototype, ensures better preservation of vitamin C, increased rate of dissolution of concentrate in water, reduced hygroscopicity, improved taste and aroma and reduced caking tendency on storage.

USE/ADVANTAGE - Used in prodn. of fruit juice concentrates. The method improves biological value of prod. and improves its stability on storage. Bul.1/7.1.93

Dwg. 0/0

?logoff

```

21jun02 15:41:24 User259289 Session D294.2
$1.12      0.348 DialUnits File155
$1.12 Estimated cost File155
$2.72      0.486 DialUnits File5
$2.72 Estimated cost File5
$14.24     0.833 DialUnits File34
$14.24 Estimated cost File34
$0.62      0.152 DialUnits File35
$0.62 Estimated cost File35
$0.74      0.163 DialUnits File51
$0.74 Estimated cost File51
$1.02      0.142 DialUnits File71
$1.02 Estimated cost File71
$5.62      0.624 DialUnits File73
$5.62 Estimated cost File73
$0.87      0.142 DialUnits File74
$0.87 Estimated cost File74
$0.84      0.165 DialUnits File76
$0.84 Estimated cost File76
$0.92      0.264 DialUnits File94
$0.92 Estimated cost File94
$2.71      0.774 DialUnits File144
$2.71 Estimated cost File144
$5.07      0.939 DialUnits File148
$13.95     9 Type(s) in Format 3 (UDF)
$5.80      2 Type(s) in Format 4 (UDF)
$19.75     11 Types
$24.82 Estimated cost File148
$0.50      0.055 DialUnits File172
$0.50 Estimated cost File172
$2.41      0.311 DialUnits File305
$2.41 Estimated cost File305
$1.39      0.096 DialUnits File342
$1.39 Estimated cost File342
$2.39      0.219 DialUnits File347
$1.60      1 Type(s) in Format 5 (UDF)
$1.60      1 Types
$3.99 Estimated cost File347
$18.45     0.713 DialUnits File351
$39.87     9 Type(s) in Format 5 (UDF)
$4.92      1 Type(s) in Format 9 (UDF)
$44.79     10 Types
$63.24 Estimated cost File351
$2.66      0.156 DialUnits File357
$2.66 Estimated cost File357
$1.78      0.104 DialUnits File434
$1.78 Estimated cost File434
$26.49     1.536 DialUnits File440
$26.49 Estimated cost File440
OneSearch, 20 files, 8.222 DialUnits FileOS
$2.60 TELNET
$161.30 Estimated cost this search

```

\$161.73 Estimated total session cost 8.304 DialUnits

### Status: Signed Off. (13 minutes)

What is claimed is:

1. A process for making a dried modified cyclodextrin product with improved dusting and aqueous dissolution properties comprising drying an aqueous solution of modified cyclodextrin on a double-drum dryer; and

recovering a dried modified cyclodextrin product with improved dusting and aqueous dissolution properties.

2. The process of claim 1 wherein said cyclodextrin is a hydroxypropylated beta-cyclodextrin.

3. The process of claim 1 wherein said drum dryer has steam-heated drums rotated at about 1 to about 5 revolutions per minute.

4. The process of claim 3 wherein said drums are heated with steam at a pressure of about 100 psig.

5. The process of claim 1 wherein about 90% or more by weight of dried product has a particle size of less than or equal to about 200 microns, and about 50% or more by weight of said product has a particle size greater than or equal to about 20 microns.

6. The method of claim 1 wherein said aqueous solution has a solids content of greater than or equal to about 45% by weight.

7. A process for making a dried agglomerated modified cyclodextrin product comprising

drying an aqueous solution of modified cyclodextrin on a double-drum dryer; and

recovering a dried agglomerated modified cyclodextrin product having a particle distribution of about 90% or more by weight less than or equal to 200 microns and about 50% or more by weight greater than or equal to 20 microns.

8. The process of claim 1 wherein said cyclodextrin is a hydroxypropylated beta-cyclodextrin.

9. The process of claim 1 wherein said drum dryer has steam-heated drums rotated at about 1 to about 5 revolutions per minute.

10. The process of claim 3 wherein said drums are heated with steam at a pressure of about 100 psig.

11. The method of claim 1 wherein said aqueous solution has a solids content of greater than or equal to about 45% by weight.

12. A dried agglomerated modified cyclodextrin product having about 90% or more by weight of said product with a particle size of less than or equal to about 200 microns; and about 50% or more by weight of said product with a particle size of greater than or equal to about 20 microns.

13. The product of claim 12 wherein said product has a dissolution time in water of less than about 5 minutes at 75°F and 10% solids.

14. The product of claim 12 wherein said product is made by a process comprising

drying an aqueous solution of modified cyclodextrin on a drum dryer; and

recovering a dried modified cyclodextrin product having said particle sizes.

15. The product of claim 12 wherein said cyclodextrin is a beta-cyclodextrin.

16. The product of claim 14 wherein said drum dryer has steam-heated drums rotated at about 1 to about 5 revolutions per minute.

17. The product of claim 16 wherein said drums are heated with steam at a pressure of about 100 psig.

18. The product of claim 14 wherein said aqueous solution has a solids content of greater than or equal to about 45% by weight.

**U.S. Standard Sieve Sizes**

<b>Standard Designation</b>	<b>Alternate Designation</b>	<b>Sieve Opening, in.</b>	<b>Wire Diameter, mm</b>
125 mm	5 in.	5	8.00
106 mm	4.24 in.	4.24	6.30
100 mm*	4 in.	4	6.30
90 mm	3 1/2 in.	3.5	6.30
75 mm	3 in.	3	6.30
63 mm	2 1/2 in.	2.5	5.60
53 mm	2.12 in.	2.12	5.00
50 mm*	2 in.	2	5.00
45 mm	1 3/4 in.	1.75	4.50
37.5 mm	1 1/2 in.	1.5	4.50
31.5 mm	1 1/4 in.	1.25	4.00
26.5 mm	1.06 in.	1.06	3.55
25.0 mm*	1.00 in.	1	3.55
22.4 mm	7/8 in.	0.875	3.55
19.0 mm	3/4 in.	0.75	3.15
16.0 mm	5/8 in.	0.625	3.15
13.2 mm	0.530 in.	0.530	2.80
12.5 mm*	1/2 in.	0.500	2.50
11.2 mm	7/16 in.	0.438	2.50
9.5 mm	3/8 in.	0.375	2.24
8.0 mm	5/16 in.	0.312	2.00
6.7 mm	0.265 in.	0.265	1.80
6.3 mm*	1/4 in.	0.250	1.80
5.6 mm	No. 3.5	0.223	1.60
4.75 mm	No. 4	0.187	1.60
4.00 mm	No. 5	0.157	1.40
3.35 mm	No. 6	0.132	1.25
2.80 mm	No. 7	0.110	1.12
2.36 mm	No. 8	0.0937	1.00
2.00 mm	No. 10	0.0787	0.900
1.7 mm	No. 12	0.0661	0.800
1.4 mm	No. 14	0.0555	0.710
1.18 mm	No. 16	0.0469	0.630
1.00 mm	No. 18	0.0394	0.560
850 µm	No. 20	0.0331	0.500
710 µm	No. 25	0.0278	0.450
600 µm	No. 30	0.0234	0.400
500 µm	No. 35	0.0197	0.315
425 µm	No. 40	0.0165	0.280
355 µm	No. 45	0.0139	0.224
300 µm	No. 50	0.0117	0.200
250 µm	No. 60	0.0098	0.160
212 µm	No. 70	0.0083	0.140
180 µm	No. 80	0.0070	0.125
150 µm	No. 100	0.0059	0.100
125 µm	No. 120	0.0049	0.090
106 µm	No. 140	0.0041	0.071
90 µm	No. 170	0.0035	0.063
75 µm	No. 200	0.0029	0.050
63 µm	No. 230	0.0025	0.045
53 µm	No. 270	0.0021	0.036
45 µm	No. 325	0.0017	0.032
38 µm	No. 400	0.0015	0.030
32 µm	No. 450	0.0012	0.028
25 µm*	No. 500	0.0010	0.025
20 µm*	No. 635	0.0008	0.020

\* Not Included in standard sieve sizes.

L7 ANSWER 2 OF 5 WPIDS (C) 2002 THOMSON DERWENT  
 ACCESSION NUMBER: 1980-22783C [13] WPIDS  
 TITLE: Excipient for powdering liq. or pasty foods - comprises  
 a  
 mixt. of cyclodextrin and dextrin of specified dextrose  
 equiv..  
 DERWENT CLASS: A11 A97 D13  
 PATENT ASSIGNEE(S): (NISH-N) NIPPON SHOKUHIN KAK  
 COUNTRY COUNT: 1  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 55021725	A	19800216	(198013)*		
JP 56044695	B	19811021	(198146)		

PRIORITY APPLN. INFO: JP 1978-93652 19780802

AB JP 55021725 A UPAB: 19930902

An excipient (I) is composed of **cyclodextrin** (II) and dextrin (III) of dextrose equiv. 5-40. The dextrose equiv. of (I) is <25. Liq. or pasty foods, are powdered by (i) mixing the food with a mixt. of (II) and (III) in a ratio such that dextrose equiv. of the mixt. is <25, and (ii) drying the mixt.

The content of (II) in (I) is pref. 10-50 wt.%. The mixt. of liq.  
 or  
 pasty food and (I) is pref. dried by drum-layer. The present method is applied to drying of soy sauce, soups of fish, meat and chicken, fruits etc.

A liq. or pasty food can be dehydrated to powder without evaporation-loss or loss of flavour. The mixt. can be easily dried at high temp. by **drum-dryer**, spray dryer, etc.